SEC Info - Nymox Pharmaceutical Corp. - ‘20-F/A’ for 12/31/20

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp. – ‘20-F/A’ for 12/31/20 – ‘EX-13.A’

On: Friday, 6/11/21, at 3:04pm ET · For: 12/31/20 · Accession #: 1640334-21-1335 · File #: 1-12033

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/11/21  Nymox Pharmaceutical Corp.        20-F/A     12/31/20    5:46K                                    Pubco Reporting … Inc/FA

Amendment to Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer — Form 20-F — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F/A      Amendment to Annual or Annual-Transition Report by  HTML     15K 
                a Foreign Non-Canadian Issuer                                    
 4: EX-13.A     Annual or Quarterly Report to Security Holders      HTML      6K 
 5: EX-13.B     Annual or Quarterly Report to Security Holders      HTML      6K 
 2: EX-12.A     Statement re: the Computation of Ratios             HTML     10K 
 3: EX-12.B     Statement re: the Computation of Ratios             HTML     10K

‘EX-13.A’ — Annual or Quarterly Report to Security Holders

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EXHIBIT 13 (a)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December 31, 2020 of Nymox Pharmaceutical Corporation (as amended) and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation

Date: June 11, 2021

By:	/s/ *Paul Averback, MD*
	Paul Averback, MD
	President and Chief Executive Officer
	Nymox Pharmaceutical Corporation

Dates Referenced Herein and Documents Incorporated by Reference

This ‘20-F/A’ Filing	Date	Other Filings

Filed on:	6/11/21
For Period end:	12/31/20	20-F
		List all Filings

↑Top

Filing Submission 0001640334-21-001335 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)